Wolff-Parkinson-White SyndromeRASAPNCT03301935
Risk Assessment in Patients With Symptomatic- and Asymptomatic Preexcitation
An observational study of Wolff-Parkinson-White Syndrome, run by Karolinska University Hospital at 1 site in Sweden.
Trial summary
Prospective cohort study including 150 patients with pre-excitation on ECG referred to our clinic for risk assessment. There will be equal numbers of symptomatic and asymptomatic patients included in the study. Each patient will perform an exercise stress test on bicycle before an invasive electrophysiological test. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Wolff-Parkinson-White Syndrome
- What is being tested?
- Electrophysiology testing and exercise stress testing
- Type of treatment
- Surgery or procedure
- How many people
- 168 participants
- Where
- 1 siteSweden
- Study dates
- 1 Dec 2016to 31 Jan 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All patients with documented ventricular preexcitation, referred for risk assessment to the Arrhythmia department at Karolinska University Hospital, were asked to participate in the study.
Who may be able to join
- Ventricular pre exciatation on 12 lead ECG
Who cannot join
- Inability to perform invasive electrophysiology testing or exercise stress test on bicycle.
Trial locations and contacts
1 site in 1 country.
About this study
Prospective cohort study including 150 patients with pre-excitation on ECG referred to our clinic for risk assessment. There will be equal numbers of symptomatic and asymptomatic patients included in the study. Each patient will perform an exercise stress test on bicycle before an invasive electrophysiological test. The purpose of this study is to compare exercise stress testing on bicycle to an invasive electrophysiological study, regarding risk assessment of patients with pre-excitation. The electrophysiology study is set as reference.
Read the detailed description
Hypothesis:
The sensitivity and specificity for exercise stress test (bicycle) is low in identifying patients with benign accessory pathways and cannot replace an invasive electrophysiological study in risk assessment of symptomatic and asymptomatic patients with pre-excitation. Invasive electrophysiological assessment should be recommended for all patients with pre-excitation despite symptoms or documented arrhythmia.
Methods:
Prospective cohort study including 150 patients with pre-excitation on ECG referred to our clinic for risk assessment. There will be equal numbers of symptomatic and asymptomatic patients included in the study. Each patient will perform an exercise stress test on bicycle before an invasive electrophysiological test. The purpose of this study is to compare exercise stress testing on bicycle to an invasive electrophysiological study, regarding risk assessment of patients with pre-excitation. The electrophysiology study is set as reference.
- Instruments and methods for analysis:
- All patients will perform an exercise stress test on a test bike according to standard protocol. ECG will be monitored closely regarding loss of pre-excitation during exercise.
- After exercise testing all patients will undergo an invasive electrophysiological study according to standard protocol.
This procedure is set as reference in identifying potentially dangerous accessory pathways.
- APERP as well as shortest R-R interval during atrial fibrillation, when applicable, will be used to characterize the conduction properties of the pathway defining high risk pathway with APERP ≤ 250 ms with or without isoprenaline.
- Inducibility in AVRT (orthodromic or antidromic reentry tachycardia) and atrial fibrillation will be recorded as well as tachycardia cycle length.
- The results of the two tests will be compared with each patient being their own control.
Programmed stimulation for risk assessment in patients with pre-excitation/accessory pathways:
- AV block or block in AP during IAP, ms
- VA block or block in AP during IVP, ms
- Antegrade curve (single ES 600 ms or longer and 400 ms): APERP And AVNERP
- Retrograde curve (single ES 600 ms): Retrograde APERP and AVNERP
- Tachycardia induction (Double ES from atrium): Inducibility
- Burst pacing from atrium
- Isoprenaline: Dose adjustment until heart rate>100/min or >50% increase from basal level.
- Antegrade curve during isoprenaline: APERP, AVNERP
- Retrograde curve during Isoprenaline:
Retrograde APERP and AVNERP
- Tachycardia induction during Isoprenaline
Statistical analysis: Sensitivity, specificity, positive predictive value and negative predictive value of exercise stress test will be assessed, using the electrophysiological study as a reference standard. A true positive and a false negative will be defined, respectively, as the persistence and the disappearance of pre-excitation in the symptomatic and asymptomatic group. A true negative and a false positive will be defined, respectively, as the disappearance and the persistence of pre-excitation in the symptomatic and asymptomatic group. Moreover, we will consider the shortest value between the minimum RR interval during atrial fibrillation and accessory pathway anterograde effective refractory period (APERP) in each patient and look for the value that could be predicted by noninvasive tests with the best combination of sensitivity, specificity, positive and negative predictive value.
Chi Square statistics will be used in comparing categorical data such as inducibility and tachycardia cycle length.
- Calculation of power: With the planned number of patients, 150, a 10% difference should be detected with a power of 80% at α 0,1.
- Expected results: We expect exercise testing to have high sensitivity, but low specificity and a low positive predictive value.
- Conditions
- Wolff-Parkinson-White Syndrome
- Being tested
- Electrophysiology testing and exercise stress testing
- Keywords
- Risk assessment
- Medical subject headings
- Wolff-Parkinson-White Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Electrophysiology testing and exercise stress testingProcedure or surgery
Each patient will perform an exercise stress test on bicycle before an invasive electrophysiological test. Both examinations will be performed according to current Clinical practice.
What is being measured
The primary outcome is the main question the study is designed to answer.
RASAP
Number of potentially dangerous pathways (i.e APERP <250 ms) identified by exercise stress test compared to the invasive electrophysiological test in the symptomatic- and asymptomatic Group.
Measured: Approximately 1 year from inclusion to 6 months follow-up.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Oct 2017
- Study start1 Dec 2016
- Primary completion31 Jan 2022
- Study completion31 Jan 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Wolff-Parkinson-White SyndromeStudies of the same condition, open and under way.
- More trials run by Karolinska University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 168 participants (actual)
Sponsor and investigators
- Lead sponsor
- Karolinska University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mats Jensen-Urstad, Karolinska University Hospital
- Investigators
- Mats Jensen-Urstad, Professor, Principal investigator, Karolinska Institutet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03301935
- Sponsor's protocol ID
- RASAP
- Acronym
- RASAP
- Status last verified
- May 2022
- First submitted
- 23 Feb 2017
- Last updated
- 24 May 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Jemtren A, Saygi S, Akerstrom F, Asaad F, Bourke T, Braunschweig F, Carnlof C, Drca N, Insulander P, Kenneback G, Nordin AP, Sadigh B, Rickenlund A, Saluveer O, Schwieler J, Svennberg E, Tapanainen J, Turkmen Y, Bastani H, Jensen-Urstad M. Risk assessment in patients with symptomatic and asymptomatic pre-excitation. Europace. 2024 Feb 1;26(2):euae036. doi: 10.1093/europace/euae036.
PubMed 38363996
Study at a glance
From the registry record, last updated by the sponsor on 24 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Risk Assessment in Patients With Symptomatic- and Asymptomatic Preexcitation
- ClinicalTrials.gov ID
- NCT03301935
- Acronym / sponsor ID
- RASAP / RASAP
- Conditions
- Wolff-Parkinson-White Syndrome
- Keywords
- Risk assessment
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 168 participants (actual)
- Lead sponsor
- Karolinska University HospitalUniversity, hospital or other
- Study start
- 1 Dec 2016 (actual)
- Primary completion
- 31 Jan 2022 (actual)
- Study completion
- 31 Jan 2022 (actual)
- First posted
- 4 Oct 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prospective cohort study including 150 patients with pre-excitation on ECG referred to our clinic for risk assessment. There will be equal numbers of symptomatic and asymptomatic patients included in the study. Each patient will perform an exercise stress test on bicycle before an invasive electrophysiological test. The purpose of this study is to compare exercise stress testing on bicycle to an invasive electrophysiological study, regarding risk assessment of patients with pre-excitation. The electrophysiology study is set as reference.
Detailed description
Hypothesis:
The sensitivity and specificity for exercise stress test (bicycle) is low in identifying patients with benign accessory pathways and cannot replace an invasive electrophysiological study in risk assessment of symptomatic and asymptomatic patients with pre-excitation. Invasive electrophysiological assessment should be recommended for all patients with pre-excitation despite symptoms or documented arrhythmia.
Methods:
Prospective cohort study including 150 patients with pre-excitation on ECG referred to our clinic for risk assessment. There will be equal numbers of symptomatic and asymptomatic patients included in the study. Each patient will perform an exercise stress test on bicycle before an invasive electrophysiological test. The purpose of this study is to compare exercise stress testing on bicycle to an invasive electrophysiological study, regarding risk assessment of patients with pre-excitation. The electrophysiology study is set as reference.
- Instruments and methods for analysis:
- All patients will perform an exercise stress test on a test bike according to standard protocol. ECG will be monitored closely regarding loss of pre-excitation during exercise.
- After exercise testing all patients will undergo an invasive electrophysiological study according to standard protocol.
This procedure is set as reference in identifying potentially dangerous accessory pathways.
- APERP as well as shortest R-R interval during atrial fibrillation, when applicable, will be used to characterize the conduction properties of the pathway defining high risk pathway with APERP ≤ 250 ms with or without isoprenaline.
- Inducibility in AVRT (orthodromic or antidromic reentry tachycardia) and atrial fibrillation will be recorded as well as tachycardia cycle length.
- The results of the two tests will be compared with each patient being their own control.
Programmed stimulation for risk assessment in patients with pre-excitation/accessory pathways:
- AV block or block in AP during IAP, ms
- VA block or block in AP during IVP, ms
- Antegrade curve (single ES 600 ms or longer and 400 ms): APERP And AVNERP
- Retrograde curve (single ES 600 ms): Retrograde APERP and AVNERP
- Tachycardia induction (Double ES from atrium): Inducibility
- Burst pacing from atrium
- Isoprenaline: Dose adjustment until heart rate>100/min or >50% increase from basal level.
- Antegrade curve during isoprenaline: APERP, AVNERP
- Retrograde curve during Isoprenaline:
Retrograde APERP and AVNERP
- Tachycardia induction during Isoprenaline
Statistical analysis: Sensitivity, specificity, positive predictive value and negative predictive value of exercise stress test will be assessed, using the electrophysiological study as a reference standard. A true positive and a false negative will be defined, respectively, as the persistence and the disappearance of pre-excitation in the symptomatic and asymptomatic group. A true negative and a false positive will be defined, respectively, as the disappearance and the persistence of pre-excitation in the symptomatic and asymptomatic group. Moreover, we will consider the shortest value between the minimum RR interval during atrial fibrillation and accessory pathway anterograde effective refractory period (APERP) in each patient and look for the value that could be predicted by noninvasive tests with the best combination of sensitivity, specificity, positive and negative predictive value.
Chi Square statistics will be used in comparing categorical data such as inducibility and tachycardia cycle length.
- Calculation of power: With the planned number of patients, 150, a 10% difference should be detected with a power of 80% at α 0,1.
- Expected results: We expect exercise testing to have high sensitivity, but low specificity and a low positive predictive value.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients with documented ventricular preexcitation, referred for risk assessment to the Arrhythmia department at Karolinska University Hospital, were asked to participate in the study.
Key inclusion criteria (1 listed)
- Ventricular pre exciatation on 12 lead ECG
Key exclusion criteria (1 listed)
- Inability to perform invasive electrophysiology testing or exercise stress test on bicycle.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Electrophysiology testing and exercise stress testingEach patient will perform an exercise stress test on bicycle before an invasive electrophysiological test. Both examinations will be performed according to current Clinical practice. | Procedure or surgery | – |
Primary outcome
RASAP
Time frame: Approximately 1 year from inclusion to 6 months follow-up.
Number of potentially dangerous pathways (i.e APERP <250 ms) identified by exercise stress test compared to the invasive electrophysiological test in the symptomatic- and asymptomatic Group.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 May 2022.
- Derived from this study: PubMed 38363996Jemtren A, Saygi S, Akerstrom F, Asaad F, Bourke T, Braunschweig F, Carnlof C, Drca N, Insulander P, Kenneback G, Nordin AP, Sadigh B, Rickenlund A, Saluveer O, Schwieler J, Svennberg E, Tapanainen J, Turkmen Y, Bastani H, Jensen-Urstad M. Risk assessment in patients with symptomatic and asymptomatic pre-excitation. Europace. 2024 Feb 1;26(2):euae036. doi: 10.1093/europace/euae036.
- Individual participant dataSharing planned: No
Related trials for Wolff-Parkinson-White Syndrome
RecruitingObservational study
AI-Based Differential Diagnosis and Localization of Tachycardia Using ECG: Multicenter Registry (EP-AI ASSIST)
Tachycardia, Paroxysmal Supraventricular Tachycardia
RecruitingPhase 1/2
ATR 1072 in Participants With PRKAG2 Syndrome
Cardiac Glycogenosis, Cardiomyopathy
Not yet recruitingObservational study
Comparative Outcomes of Radiofrequency Ablation of Concealed and Manifest Accessory Pathways: a Single Center, Retrospective Observational Study
Atrioventricular Reentrant Tachycardias, Wolff-Parkinson-White (WPW) Syndrome
Active, not recruitingObservational study
Longitudinal Evaluation of Active-Duty Personnel with Accessory Pathways (LEAD-AP)
Cardiac Death, Cardiac Death, Sudden
RecruitingObservational study
Discrimination of Right Versus Left Septal Accessory Pathway Before and During the Electrophysiological Study
WPW Syndrome, Accessory Pathway
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mats Jensen-Urstad, Professor principal investigator
Karolinska Institutet
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Wolff-Parkinson-White Syndrome, run by Karolinska University Hospital at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
RASAP (time frame: Approximately 1 year from inclusion to 6 months follow-up.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03301935, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 May 2022.